Chronic myeloid leukaemia (CML) is a malignancy of the haematopoietic stem cells. The first
line of treatment for CML, especially in developing countries, remains the first‐generation
tyrosine kinase inhibitor, Imatinib. Patients with CML are frequently diagnosed with platelet
abnormalities. However, the specific mechanism of platelet abnormalities in CML remains
unclear and poorly understood. The aim of this study was therefore to determine the
apoptotic profiles of CML patients ex vivo on platelets before and after treatment with …